{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:09:05Z","timestamp":1792192145600,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ca232979"],"award-info":[{"award-number":["ca232979"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ca097098"],"award-info":[{"award-number":["ca097098"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ca166480"],"award-info":[{"award-number":["ca166480"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ca216553"],"award-info":[{"award-number":["ca216553"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["ca229716"],"award-info":[{"award-number":["ca229716"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies. The oncogenic MUC1-C protein is overexpressed in castration-resistant prostate cancer (CRPC) and NEPC, but its specific role is unknown. Here, we demonstrate that upregulation of MUC1-C in androgen-dependent PC cells suppresses androgen receptor (AR) axis signaling and induces the neural BRN2 transcription factor. MUC1-C activates a MYC\u2192BRN2 pathway in association with induction of MYCN, EZH2 and NE differentiation markers (ASCL1, AURKA and SYP) linked to NEPC progression. Moreover, MUC1-C suppresses the p53 pathway, induces the Yamanaka pluripotency factors (OCT4, SOX2, KLF4 and MYC) and drives stemness. Targeting MUC1-C decreases PC self-renewal capacity and tumorigenicity, suggesting a potential therapeutic approach for CRPC and NEPC. In PC tissues, MUC1 expression associates with suppression of AR signaling and increases in BRN2 expression and NEPC score. These results highlight MUC1-C as a master effector of lineage plasticity driving progression to NEPC.<\/jats:p>","DOI":"10.1038\/s41467-019-14219-6","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:03:05Z","timestamp":1579258985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Yota","family":"Yasumizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caining","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Pitroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-8176","authenticated-orcid":false,"given":"Mark D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-5539","authenticated-orcid":false,"given":"Qiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Kui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-4594","authenticated-orcid":false,"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-235X","authenticated-orcid":false,"given":"Kwok K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-8888","authenticated-orcid":false,"given":"Donald","family":"Kufe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"14219_CR1","doi-asserted-by":"crossref","first-page":"a030593","DOI":"10.1101\/cshperspect.a030593","volume":"9","author":"L Puca","year":"2019","unstructured":"Puca, L., Vlachostergios, P. J. & Beltran, H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb. Perspect. Med. 9, a030593 (2019).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"14219_CR2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271\u2013286 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"14219_CR3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492\u20132503 (2018).","journal-title":"J. Clin. Oncol."},{"key":"14219_CR4","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14219_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nm.4341","volume":"23","author":"DS Rickman","year":"2017","unstructured":"Rickman, D. S., Beltran, H., Demichelis, F. & Rubin, M. A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med 23, 1\u201310 (2017).","journal-title":"Nat. Med"},{"key":"14219_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu, P. et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84\u201388 (2017).","journal-title":"Science"},{"key":"14219_CR7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017).","journal-title":"Cancer Discov."},{"key":"14219_CR8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487\u2013495 (2011).","journal-title":"Cancer Discov."},{"key":"14219_CR9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016).","journal-title":"Nat. Med."},{"key":"14219_CR10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"J Lee","year":"2016","unstructured":"Lee, J. et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell 29, 536\u2013547 (2016).","journal-title":"Cancer Cell"},{"key":"14219_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"14219_CR12","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"130","author":"A Berger","year":"2019","unstructured":"Berger, A. et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J. Clin. Invest. 130, 3924\u20133940 (2019).","journal-title":"J. Clin. Invest"},{"key":"14219_CR13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"D Kufe","year":"2009","unstructured":"Kufe, D. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874\u2013885 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"14219_CR14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2012.158","volume":"32","author":"D Kufe","year":"2013","unstructured":"Kufe, D. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32, 1073\u20131081 (2013).","journal-title":"Oncogene"},{"key":"14219_CR15","first-page":"117","volume":"1868","author":"H Rajabi","year":"2017","unstructured":"Rajabi, H. & Kufe, D. MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas. BBA Rev. Cancer 1868, 117\u2013122 (2017).","journal-title":"BBA Rev. Cancer"},{"key":"14219_CR16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41388-017-0096-9","volume":"37","author":"H Rajabi","year":"2018","unstructured":"Rajabi, H., Hiraki, M. & Kufe, D. MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene 37, 2079\u20132088 (2018).","journal-title":"Oncogene"},{"key":"14219_CR17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1073\/pnas.0304146101","volume":"101","author":"J Lapointe","year":"2004","unstructured":"Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811\u2013816 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14219_CR18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.bjc.6603944","volume":"97","author":"O Andr\u00e9n","year":"2007","unstructured":"Andr\u00e9n, O. et al. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br. J. Cancer 97, 730\u2013734 (2007).","journal-title":"Br. J. Cancer"},{"key":"14219_CR19","doi-asserted-by":"crossref","first-page":"e0165236","DOI":"10.1371\/journal.pone.0165236","volume":"11","author":"O Eminaga","year":"2016","unstructured":"Eminaga, O. et al. MUC1 expression by immunohistochemistry is associated with adverse pathologic features in prostate cancer: a multi-institutional study. PLoS ONE 11, e0165236 (2016).","journal-title":"PLoS ONE"},{"key":"14219_CR20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/pcan.2016.11","volume":"19","author":"V Genitsch","year":"2016","unstructured":"Genitsch, V., Zlobec, I., Thalmann, G. N. & Fleischmann, A. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor. Prostate Cancer Prostatic Dis. 19, 242\u2013247 (2016).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"14219_CR21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neo.2017.06.006","volume":"19","author":"X Lin","year":"2017","unstructured":"Lin, X. et al. Overexpression of MUC1 and genomic alterations in its network associate with prostate cancer progression. Neoplasia 19, 857\u2013867 (2017).","journal-title":"Neoplasia"},{"key":"14219_CR22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2005.01.008","volume":"7","author":"X Wei","year":"2005","unstructured":"Wei, X., Xu, H. & Kufe, D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7, 167\u2013178 (2005).","journal-title":"Cancer Cell"},{"key":"14219_CR23","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/0008-5472.CAN-19-1034","volume":"79","author":"T Hata","year":"2019","unstructured":"Hata, T. et al. MUC1-C activates the NuRD complex to drive dedifferentiation of triple-negative breast cancer cells. Cancer Res. 79, 5711\u20135722 (2019).","journal-title":"Cancer Res"},{"key":"14219_CR24","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1038\/s41388-019-0940-1","volume":"38","author":"H Rajabi","year":"2019","unstructured":"Rajabi, H. et al. MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene 38, 7266\u20137277 (2019).","journal-title":"Oncogene"},{"key":"14219_CR25","first-page":"2577","volume":"54","author":"GN Thalmann","year":"1994","unstructured":"Thalmann, G. N. et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54, 2577\u20132581 (1994).","journal-title":"Cancer Res."},{"key":"14219_CR26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein, J. I. et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 38, 756\u2013767 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"14219_CR27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","volume":"32","author":"W Wang","year":"2008","unstructured":"Wang, W. & Epstein, J. I. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 32, 65\u201371 (2008).","journal-title":"Am. J. Surg. Pathol."},{"key":"14219_CR28","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/0008-5472.CAN-15-1804","volume":"76","author":"A Bouillez","year":"2016","unstructured":"Bouillez, A. et al. Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas. Cancer Res. 76, 1538\u20131548 (2016).","journal-title":"Cancer Res."},{"key":"14219_CR29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/1541-7786.MCR-16-0233","volume":"14","author":"M Alam","year":"2016","unstructured":"Alam, M. et al. MUC1-C represses the Crumbs complex polarity factor CRB3 and downregulates the Hippo pathway. Mol. Cancer Res. 14, 1266\u20131276 (2016).","journal-title":"Mol. Cancer Res."},{"key":"14219_CR30","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.2147\/OTT.S168813","volume":"11","author":"Z Xin","year":"2018","unstructured":"Xin, Z. et al. Inhibition of MUC1-C entering nuclear suppresses MYC expression and attenuates malignant growth in esophageal squamous cell carcinoma. Onco Targets Ther. 11, 4125\u20134136 (2018).","journal-title":"Onco Targets Ther."},{"key":"14219_CR31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.2910210305","volume":"21","author":"KR Stone","year":"1978","unstructured":"Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H. & Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 21, 274\u2013281 (1978).","journal-title":"Int. J. Cancer"},{"key":"14219_CR32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1593\/neo.07103","volume":"9","author":"KD Mertz","year":"2007","unstructured":"Mertz, K. D. et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200\u2013206 (2007).","journal-title":"Neoplasia"},{"key":"14219_CR33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"14219_CR34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"14219_CR35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07850-0","volume":"7","author":"H Rajabi","year":"2017","unstructured":"Rajabi, H. et al. MUC1-C activates EZH2 expression and function in human cancer cells. Sci. Rep. 7, 7481 (2017).","journal-title":"Sci. Rep."},{"key":"14219_CR36","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/onc.2016.439","volume":"36","author":"M Hiraki","year":"2017","unstructured":"Hiraki, M. et al. MUC1-C activates BMI1 in human cancer cells. Oncogene 36, 2791\u20132801 (2017).","journal-title":"Oncogene"},{"key":"14219_CR37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent, L. N. & Leone, G. The broken cycle: E2F dysfunction in cancer. Nat. Rev. Cancer 19, 326\u2013338 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"14219_CR38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.celrep.2015.07.012","volume":"12","author":"S Akamatsu","year":"2015","unstructured":"Akamatsu, S. et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 12, 922\u2013936 (2015).","journal-title":"Cell Rep."},{"key":"14219_CR39","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/cercor\/bhs252","volume":"23","author":"MH Dominguez","year":"2013","unstructured":"Dominguez, M. H., Ayoub, A. E. & Rakic, P. POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex. Cereb. Cortex 23, 2632\u20132643 (2013).","journal-title":"Cereb. Cortex"},{"key":"14219_CR40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","volume":"17","author":"K Takahashi","year":"2016","unstructured":"Takahashi, K. & Yamanaka, S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell Biol. 17, 183\u2013193 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"14219_CR41","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1158\/1535-7163.MCT-09-0646","volume":"8","author":"MD Joshi","year":"2009","unstructured":"Joshi, M. D. et al. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol. Cancer Ther. 8, 3056\u20133065 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"14219_CR42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-10-1050","volume":"10","author":"D Raina","year":"2011","unstructured":"Raina, D. et al. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol. Cancer Ther. 10, 806\u2013816 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"14219_CR43","first-page":"1643","volume":"40","author":"D Raina","year":"2012","unstructured":"Raina, D. et al. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J. Oncol. 40, 1643\u20131649 (2012).","journal-title":"Int J. Oncol."},{"key":"14219_CR44","doi-asserted-by":"crossref","first-page":"e0135156","DOI":"10.1371\/journal.pone.0135156","volume":"10","author":"D Raina","year":"2015","unstructured":"Raina, D. et al. Characterization of the MUC1-C cytoplasmic domain as a cancer target. PLoS ONE 10, e0135156 (2015).","journal-title":"PLoS ONE"},{"key":"14219_CR45","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/0008-5472.CAN-09-0854","volume":"69","author":"D Raina","year":"2009","unstructured":"Raina, D. et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 69, 5133\u20135141 (2009).","journal-title":"Cancer Res"},{"key":"14219_CR46","doi-asserted-by":"crossref","first-page":"e43020","DOI":"10.1371\/journal.pone.0043020","volume":"7","author":"S Banerjee","year":"2012","unstructured":"Banerjee, S. et al. MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. PloS ONE 7, e43020 (2012).","journal-title":"PloS ONE"},{"key":"14219_CR47","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-13-3168","volume":"20","author":"A Kharbanda","year":"2014","unstructured":"Kharbanda, A. et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin. Cancer Res. 20, 5423\u20135434 (2014).","journal-title":"Clin. Cancer Res."},{"key":"14219_CR48","doi-asserted-by":"crossref","first-page":"12019","DOI":"10.1002\/jcp.27863","volume":"234","author":"X GongSun","year":"2019","unstructured":"GongSun, X. et al. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma. J. Cell Physiol. 234, 12019\u201312028 (2019).","journal-title":"J. Cell Physiol."},{"key":"14219_CR49","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-14-3000","volume":"21","author":"M Hasegawa","year":"2015","unstructured":"Hasegawa, M. et al. Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation. Clin. Cancer Res. 21, 2338\u20132347 (2015).","journal-title":"Clin. Cancer Res"},{"key":"14219_CR50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"14219_CR51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research Network.","year":"2015","unstructured":"Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"14219_CR52","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"14219_CR53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","volume":"25","author":"S Akamatsu","year":"2018","unstructured":"Akamatsu, S., Inoue, T., Ogawa, O. & Gleave, M. E. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int. J. Urol. 25, 345\u2013351 (2018).","journal-title":"Int. J. Urol."},{"key":"14219_CR54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/pros.21344","volume":"71","author":"H Rajabi","year":"2011","unstructured":"Rajabi, H., Joshi, M. D., Jin, C., Ahmad, R. & Kufe, D. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate 71, 1299\u20131308 (2011).","journal-title":"Prostate"},{"key":"14219_CR55","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/pros.22519","volume":"72","author":"H Rajabi","year":"2012","unstructured":"Rajabi, H. et al. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate 72, 1659\u20131668 (2012).","journal-title":"Prostate"},{"key":"14219_CR56","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-015-0074-4","volume":"7","author":"PL Clermont","year":"2015","unstructured":"Clermont, P. L. et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin. Epigenetics 7, 40 (2015).","journal-title":"Clin. Epigenetics"},{"key":"14219_CR57","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1158\/0008-5472.CAN-06-3063","volume":"67","author":"X Wei","year":"2007","unstructured":"Wei, X., Xu, H. & Kufe, D. Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 67, 1853\u20131858 (2007).","journal-title":"Cancer Res"},{"key":"14219_CR58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.stem.2014.10.019","volume":"16","author":"MS Kareta","year":"2015","unstructured":"Kareta, M. S. et al. Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 16, 39\u201350 (2015).","journal-title":"Cell Stem Cell"},{"key":"14219_CR59","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-cancerbio-030617-050224","volume":"2","author":"C Le Magnen","year":"2018","unstructured":"Le Magnen, C., Shen, M. M. & Abate-Shen, C. Lineage plasticity in cancer progression and treatment. Annu Rev. Cancer Biol. 2, 271\u2013289 (2018).","journal-title":"Annu Rev. Cancer Biol."},{"key":"14219_CR60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.stem.2018.11.011","volume":"24","author":"PB Gupta","year":"2019","unstructured":"Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C. & Kuperwasser, C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 24, 65\u201378 (2019).","journal-title":"Cell Stem Cell"},{"key":"14219_CR61","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran, H. et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin. Cancer Res. 25, 6916\u20136924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"14219_CR62","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1038\/sj.onc.1206732","volume":"22","author":"Y Li","year":"2003","unstructured":"Li, Y., Liu, D., Chen, D., Kharbanda, S. & Kufe, D. Human DF3\/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22, 6107\u20136110 (2003).","journal-title":"Oncogene"},{"key":"14219_CR63","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1096\/fj.201600387R","volume":"30","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Numb and Numbl act to determine mammary myoepithelial cell fate, maintain epithelial identity, and support lactogenesis. FASEB J. 30, 3474\u20133488 (2016).","journal-title":"FASEB J."},{"key":"14219_CR64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.devcel.2014.03.006","volume":"29","author":"K Watanabe","year":"2014","unstructured":"Watanabe, K. et al. Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. Dev. Cell 29, 59\u201374 (2014).","journal-title":"Dev. Cell"},{"key":"14219_CR65","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1038\/onc.2014.442","volume":"34","author":"H Takahashi","year":"2015","unstructured":"Takahashi, H. et al. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene 34, 5187\u20135197 (2015).","journal-title":"Oncogene"},{"key":"14219_CR66","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1535-7163.MCT-19-0156","volume":"18","author":"T Hata","year":"2019","unstructured":"Hata, T. et al. Targeting MUC1-C inhibits TWIST1 signaling in triple-negative breast cancer. Mol. Cancer Ther. 18, 1744\u20131754 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"14219_CR67","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pros.22814","volume":"74","author":"R Shao","year":"2014","unstructured":"Shao, R. et al. Epithelial-to-mesenchymal transition and estrogen receptor alpha mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia. Prostate 74, 970\u2013982 (2014).","journal-title":"Prostate"},{"key":"14219_CR68","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1073\/pnas.0812666106","volume":"106","author":"P Alonso-Magdalena","year":"2009","unstructured":"Alonso-Magdalena, P. et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl Acad. Sci. USA 106, 2859\u20132863 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14219_CR69","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4081\/aiua.2017.4.259","volume":"89","author":"G Perletti","year":"2017","unstructured":"Perletti, G. et al. The association between prostatitis and prostate cancer. Systematic review and meta-analysis. Arch. Ital. Urol. Androl. 89, 259\u2013265 (2017).","journal-title":"Arch. Ital. Urol. Androl."},{"key":"14219_CR70","doi-asserted-by":"crossref","first-page":"e99880","DOI":"10.1172\/jci.insight.99880","volume":"3","author":"G Panchamoorthy","year":"2018","unstructured":"Panchamoorthy, G. et al. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight 3, e99880 (2018).","journal-title":"JCI Insight"}],"updated-by":[{"DOI":"10.1038\/s41467-020-14808-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14219-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14219-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:01:50Z","timestamp":1670259710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14219-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14219"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-14219-6","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-020-14808-w","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"5 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.K. has equity interests in Genus Oncology, Reata Pharmaceuticals, Hillstream BioPharma, Nanogen Therapeutics and Victa BioTherapeutics, serves as a member of the board of directors of Nanogen and Victa, and is a paid consultant to Reata, CanBas and Victa. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}